AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026?

Choosing between AbbVie (NYSE:ABBV) and Novo Nordisk (NYSE:NVO) requires balancing a diversified income play against a focused growth leader in the massive metabolic health market during 2026.

AbbVie has historically relied on blockbuster drugs while aggressively acquiring new pipelines to maintain its market share. Meanwhile, Novo Nordisk has seen a surge in demand for its GLP-1 therapies, positioning itself as a dominant force in chronic disease management across the globe.

The case for AbbVie

AbbVie operates as a diversified biopharmaceutical company that targets complex conditions in immunology, oncology, and neuroscience. Its primary customers include wholesale distributors, hospitals, and pharmacy benefit managers who facilitate the delivery of high-cost specialty drugs. In the United States, three wholesale distributors, McKesson Corp (NYSE:MCK), Cardinal Health (NYSE:CAH), and Cencora (NYSE:COR), account for nearly all pharmaceutical product sales. Customer concentration like this adds a layer of risk to the business, as the company relies heavily on these specific channels for its revenue.

In its latest annual report, filed for FY 2025, revenue reached roughly $61.2 billion, representing a ~9% increase over the prior year. The company reported net income of close to $4.3 billion, resulting in a net margin of approximately 7%. This net margin, which measures how much profit the company keeps for every dollar of sales, reflects the costs associated with integrating new acquisitions and managing its extensive global manufacturing operations. Revenue growth has remained positive as the company successfully launched new products to replace sales from older medications facing competition.

As of its December 2025 balance sheet, the company reported a debt-to-equity ratio of negative 21.1x, indicating that total liabilities exceed shareholder equity. Its so-called current ratio stands at approximately 0.7x, which measures a company's ability to cover its short-term obligations with assets that can be converted to cash within one year. Despite the negative equity position, the company generated free cash flow of nearly $17.8 billion in FY 2025. Free cash flow represents the cash a company generates after accounting for cash outflows to support operations and maintain its capital assets, providing the funds necessary for dividends and debt repayment.

The case for Novo Nordisk

Novo Nordisk has built a formidable presence among pharmaceutical stocks by focusing on metabolic diseases, including diabetes and obesity. The company markets its products in roughly 170 countries, utilizing a vast network of international affiliates to maintain its global leadership. Its strategy centers on the continued expansion of its GLP-1 portfolio, which has seen unprecedented demand as healthcare providers prioritize weight management treatments alongside traditional insulin therapies.

In FY 2025, its most recently concluded fiscal year, revenue reached approximately $47 billion, a growth rate of close to 6.4% compared to the previous fiscal period. (The company reports in Danish kroner; the figures have been converted to U.S. dollars). Net income for the year was nearly $16 billion, producing a robust net margin of roughly 33%. This high net margin suggests the company operates with significant pricing power and efficiency in its core therapeutic areas. While revenue growth was slightly lower than its peer, the absolute level of net income indicates a highly profitable business model that benefits from the recurring nature of chronic disease treatments.

According to its December 2025 balance sheet, the debt-to-equity ratio is approximately 0.7x, showing a conservative balance between borrowed funds and shareholder equity. Its current ratio stands at nearly 0.8x, suggesting the company manages its short-term liquidity needs closely relative to its available cash and receivables. Free cash flow for FY 2025 was roughly $4.4 billion. This cash generation supports the company's research into rare diseases and cardiovascular health, ensuring it remains competitive as patent landscapes shift in the metabolic sector.

Risk profile comparison

AbbVie faces significant revenue risks from the expiration of intellectual property for several key products, which often leads to competition from lower-cost biosimilars. The Inflation Reduction Act also presents a challenge, as it allows for government-negotiated pricing on major products like Imbruvica and Botox, potentially eroding future revenue. Furthermore, the company is involved in ongoing product liability litigation and relies on a concentrated supply chain for critical raw materials. Success in its business model remains dependent on high-risk research and development that offers no guarantee of commercial approval.

Novo Nordisk operates in a highly competitive environment where rival manufacturers, including GSK plc (NYSE:GSK), are constantly developing competing therapies for diabetes and respiratory issues. The company faces risks related to manufacturing capacity, as the surge in demand for its obesity treatments has previously led to supply constraints. Legislative changes in various international markets regarding drug pricing could also impact its net margin over time. Additionally, any safety concerns or regulatory hurdles related to its primary GLP-1 products could significantly disrupt its growth trajectory and market valuation.

Valuation comparison

Novo Nordisk appears to be the more attractively valued option based on both earnings and sales multiples despite having slightly slower revenue growth in FY 2025.

Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Which stock would I buy in 2026?

Novo Nordisk has the blockbuster drugs Wegovy and Ozempic (the same drug marketed for different purposes) but faces investor doubts about its market position given a deal with the federal government to lower prices for the GLP-1s, the emergence of generic competitors, and the apparent advances by Eli Lilly & Co (NYSE:LLY) in developing weight loss drugs expected to be superior to Novo's offerings.

Still, the introduction of the once a day Wegovy pill in the U.S. has been a resounding success and the business has a patent on injectable Ozempic/Wegovy till 2032, providing it some competitive moat. Still, Wall Street sees sales declining in fiscal 2026 by about 3% with net income contracting 4% as pricing pressures erode margins just a bit. Longer-term, analysts expect the company to reverse the 2026 decline and start growing again as new products come on line.

AbbVie has a drug pipeline that some on Wall Street believe could include blockbusters (more than $1 billion in lifetime revenue) for treating schizophrenia, Parkinson's disease, psychosis from Alzheimer's, and certain solid tumors.

On top of that, the business is buying itself additional growth with its recent deal to acquire Apogee Therapeutics. Its two relatively new immunology products, Skyrizi and Rinvoq, have proven to be true growth drivers for the business, and investors are hopeful that an FDA decision on a Parkinson's treatment later this year will bode well for the company. AbbVie is expected to see screaming growth in net income this year, from $4.2 billion to $14.6 billion. Sales should grow to $67.2 billion.

Novo Nordisk invented the GL-1 market. Even as it faces intense competition, it is hard to ignore its first mover and current market advantages. AbbVie's near-term growth is impressive, but Novo Nordisk offers the more attractive option based on its currently lower ratios for forward earnings and sales.

Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie and Novo Nordisk. The Motley Fool recommends GSK and McKesson. The Motley Fool has a disclosure policy.